Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
25
OGI Quote, Financials, Valuation and Earnings
Last price:
$1.40
Seasonality move
:
0.34%
Day range:
$1.32 - $1.40
52-week range:
$0.85 - $2.24
Dividend yield:
0%
P/E ratio:
15.77x
P/S ratio:
0.92x
P/B ratio:
0.69x
Volume:
636K
Avg. volume:
728.5K
1-year change:
28.04%
Market cap:
$185.1M
Revenue:
$185.4M
EPS (TTM):
$0.09
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
OGI
Organigram Global, Inc.
|
$53.5M | -$0.01 | 14.67% | -95.15% | -- |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$74.7M | $0.22 | 23.24% | 31.9% | $17.00 |
|
EDSA
Edesa Biotech, Inc.
|
-- | -- | -- | -- | $11.00 |
|
LEXX
Lexaria Bioscience Corp.
|
$50K | -- | -42.53% | -- | $3.75 |
|
ONCY
Oncolytics Biotech, Inc.
|
-- | -$0.06 | -- | -9.85% | $5.54 |
|
TLRY
Tilray Brands, Inc.
|
$201.5M | $0.07 | 8.44% | -100% | $11.73 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
OGI
Organigram Global, Inc.
|
$1.37 | -- | $185.1M | 15.77x | $0.00 | 0% | 0.92x |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$14.15 | $17.00 | $1.9B | 6.81x | $0.00 | 0% | 6.93x |
|
EDSA
Edesa Biotech, Inc.
|
$4.35 | $11.00 | $36.3M | -- | $0.00 | 0% | 31.22x |
|
LEXX
Lexaria Bioscience Corp.
|
$0.68 | $3.75 | $16.8M | -- | $0.00 | 0% | 24.81x |
|
ONCY
Oncolytics Biotech, Inc.
|
$1.04 | $5.54 | $111.9M | -- | $0.00 | 0% | -- |
|
TLRY
Tilray Brands, Inc.
|
$7.36 | $11.73 | $853.8M | -- | $0.00 | 0% | 0.89x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
OGI
Organigram Global, Inc.
|
2.24% | 1.683 | 2.72% | 1.24x |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
11.4% | 0.024 | 3.56% | 4.69x |
|
EDSA
Edesa Biotech, Inc.
|
-- | -2.737 | -- | 16.51x |
|
LEXX
Lexaria Bioscience Corp.
|
2.03% | -0.580 | 0.43% | 3.04x |
|
ONCY
Oncolytics Biotech, Inc.
|
87.89% | 4.535 | 0.41% | 1.61x |
|
TLRY
Tilray Brands, Inc.
|
16.83% | 2.226 | 35.13% | 1.54x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
OGI
Organigram Global, Inc.
|
$3.1M | -$14.4M | 4.43% | 4.54% | -31.68% | -$12.8M |
|
AUPH
Aurinia Pharmaceuticals, Inc.
|
$68.3M | $28.2M | 59.78% | 71.44% | 36.52% | $44.5M |
|
EDSA
Edesa Biotech, Inc.
|
-$25.5K | -$2.3M | -66.98% | -66.98% | -- | -$2.1M |
|
LEXX
Lexaria Bioscience Corp.
|
-$24.2K | -$1.6M | -186.06% | -189.86% | -2155.4% | -$989.2K |
|
ONCY
Oncolytics Biotech, Inc.
|
-$67.5K | -$10M | -540.79% | -635.07% | -- | -$4.9M |
|
TLRY
Tilray Brands, Inc.
|
$53.1M | -$20M | -84.8% | -98.18% | -9.2% | -$18M |
Organigram Global, Inc. vs. Competitors
-
Which has Higher Returns OGI or AUPH?
Aurinia Pharmaceuticals, Inc. has a net margin of 31.43% compared to Organigram Global, Inc.'s net margin of 42.95%. Organigram Global, Inc.'s return on equity of 4.54% beat Aurinia Pharmaceuticals, Inc.'s return on equity of 71.44%.
Company Gross Margin Earnings Per Share Invested Capital OGIOrganigram Global, Inc.6.91% $0.10 $275.7M AUPHAurinia Pharmaceuticals, Inc.88.59% $1.53 $656.1M -
What do Analysts Say About OGI or AUPH?
Organigram Global, Inc. has a consensus price target of --, signalling upside risk potential of 137.96%. On the other hand Aurinia Pharmaceuticals, Inc. has an analysts' consensus of $17.00 which suggests that it could grow by 20.14%. Given that Organigram Global, Inc. has higher upside potential than Aurinia Pharmaceuticals, Inc., analysts believe Organigram Global, Inc. is more attractive than Aurinia Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings OGIOrganigram Global, Inc.4 0 0 AUPHAurinia Pharmaceuticals, Inc.4 3 0 -
Is OGI or AUPH More Risky?
Organigram Global, Inc. has a beta of 1.512, which suggesting that the stock is 51.228% more volatile than S&P 500. In comparison Aurinia Pharmaceuticals, Inc. has a beta of 1.535, suggesting its more volatile than the S&P 500 by 53.466%.
-
Which is a Better Dividend Stock OGI or AUPH?
Organigram Global, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aurinia Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Organigram Global, Inc. pays -- of its earnings as a dividend. Aurinia Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OGI or AUPH?
Organigram Global, Inc. quarterly revenues are $45.6M, which are smaller than Aurinia Pharmaceuticals, Inc. quarterly revenues of $77.1M. Organigram Global, Inc.'s net income of $14.3M is lower than Aurinia Pharmaceuticals, Inc.'s net income of $210.8M. Notably, Organigram Global, Inc.'s price-to-earnings ratio is 15.77x while Aurinia Pharmaceuticals, Inc.'s PE ratio is 6.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organigram Global, Inc. is 0.92x versus 6.93x for Aurinia Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OGIOrganigram Global, Inc.0.92x 15.77x $45.6M $14.3M AUPHAurinia Pharmaceuticals, Inc.6.93x 6.81x $77.1M $210.8M
-
Which has Higher Returns OGI or EDSA?
Edesa Biotech, Inc. has a net margin of 31.43% compared to Organigram Global, Inc.'s net margin of --. Organigram Global, Inc.'s return on equity of 4.54% beat Edesa Biotech, Inc.'s return on equity of -66.98%.
Company Gross Margin Earnings Per Share Invested Capital OGIOrganigram Global, Inc.6.91% $0.10 $275.7M EDSAEdesa Biotech, Inc.-- -$0.28 $14M -
What do Analysts Say About OGI or EDSA?
Organigram Global, Inc. has a consensus price target of --, signalling upside risk potential of 137.96%. On the other hand Edesa Biotech, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 152.87%. Given that Edesa Biotech, Inc. has higher upside potential than Organigram Global, Inc., analysts believe Edesa Biotech, Inc. is more attractive than Organigram Global, Inc..
Company Buy Ratings Hold Ratings Sell Ratings OGIOrganigram Global, Inc.4 0 0 EDSAEdesa Biotech, Inc.2 0 0 -
Is OGI or EDSA More Risky?
Organigram Global, Inc. has a beta of 1.512, which suggesting that the stock is 51.228% more volatile than S&P 500. In comparison Edesa Biotech, Inc. has a beta of 0.049, suggesting its less volatile than the S&P 500 by 95.095%.
-
Which is a Better Dividend Stock OGI or EDSA?
Organigram Global, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Organigram Global, Inc. pays -- of its earnings as a dividend. Edesa Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OGI or EDSA?
Organigram Global, Inc. quarterly revenues are $45.6M, which are larger than Edesa Biotech, Inc. quarterly revenues of --. Organigram Global, Inc.'s net income of $14.3M is higher than Edesa Biotech, Inc.'s net income of -$2.2M. Notably, Organigram Global, Inc.'s price-to-earnings ratio is 15.77x while Edesa Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organigram Global, Inc. is 0.92x versus 31.22x for Edesa Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OGIOrganigram Global, Inc.0.92x 15.77x $45.6M $14.3M EDSAEdesa Biotech, Inc.31.22x -- -- -$2.2M
-
Which has Higher Returns OGI or LEXX?
Lexaria Bioscience Corp. has a net margin of 31.43% compared to Organigram Global, Inc.'s net margin of -2178.51%. Organigram Global, Inc.'s return on equity of 4.54% beat Lexaria Bioscience Corp.'s return on equity of -189.86%.
Company Gross Margin Earnings Per Share Invested Capital OGIOrganigram Global, Inc.6.91% $0.10 $275.7M LEXXLexaria Bioscience Corp.91.15% -$0.07 $4.6M -
What do Analysts Say About OGI or LEXX?
Organigram Global, Inc. has a consensus price target of --, signalling upside risk potential of 137.96%. On the other hand Lexaria Bioscience Corp. has an analysts' consensus of $3.75 which suggests that it could grow by 455.56%. Given that Lexaria Bioscience Corp. has higher upside potential than Organigram Global, Inc., analysts believe Lexaria Bioscience Corp. is more attractive than Organigram Global, Inc..
Company Buy Ratings Hold Ratings Sell Ratings OGIOrganigram Global, Inc.4 0 0 LEXXLexaria Bioscience Corp.1 0 0 -
Is OGI or LEXX More Risky?
Organigram Global, Inc. has a beta of 1.512, which suggesting that the stock is 51.228% more volatile than S&P 500. In comparison Lexaria Bioscience Corp. has a beta of 0.541, suggesting its less volatile than the S&P 500 by 45.863%.
-
Which is a Better Dividend Stock OGI or LEXX?
Organigram Global, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Organigram Global, Inc. pays -- of its earnings as a dividend. Lexaria Bioscience Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OGI or LEXX?
Organigram Global, Inc. quarterly revenues are $45.6M, which are larger than Lexaria Bioscience Corp. quarterly revenues of --. Organigram Global, Inc.'s net income of $14.3M is higher than Lexaria Bioscience Corp.'s net income of -$1.6M. Notably, Organigram Global, Inc.'s price-to-earnings ratio is 15.77x while Lexaria Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organigram Global, Inc. is 0.92x versus 24.81x for Lexaria Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OGIOrganigram Global, Inc.0.92x 15.77x $45.6M $14.3M LEXXLexaria Bioscience Corp.24.81x -- -- -$1.6M
-
Which has Higher Returns OGI or ONCY?
Oncolytics Biotech, Inc. has a net margin of 31.43% compared to Organigram Global, Inc.'s net margin of --. Organigram Global, Inc.'s return on equity of 4.54% beat Oncolytics Biotech, Inc.'s return on equity of -635.07%.
Company Gross Margin Earnings Per Share Invested Capital OGIOrganigram Global, Inc.6.91% $0.10 $275.7M ONCYOncolytics Biotech, Inc.-- -$0.10 $682.8K -
What do Analysts Say About OGI or ONCY?
Organigram Global, Inc. has a consensus price target of --, signalling upside risk potential of 137.96%. On the other hand Oncolytics Biotech, Inc. has an analysts' consensus of $5.54 which suggests that it could grow by 432.25%. Given that Oncolytics Biotech, Inc. has higher upside potential than Organigram Global, Inc., analysts believe Oncolytics Biotech, Inc. is more attractive than Organigram Global, Inc..
Company Buy Ratings Hold Ratings Sell Ratings OGIOrganigram Global, Inc.4 0 0 ONCYOncolytics Biotech, Inc.3 1 0 -
Is OGI or ONCY More Risky?
Organigram Global, Inc. has a beta of 1.512, which suggesting that the stock is 51.228% more volatile than S&P 500. In comparison Oncolytics Biotech, Inc. has a beta of 0.923, suggesting its less volatile than the S&P 500 by 7.708%.
-
Which is a Better Dividend Stock OGI or ONCY?
Organigram Global, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncolytics Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Organigram Global, Inc. pays -- of its earnings as a dividend. Oncolytics Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OGI or ONCY?
Organigram Global, Inc. quarterly revenues are $45.6M, which are larger than Oncolytics Biotech, Inc. quarterly revenues of --. Organigram Global, Inc.'s net income of $14.3M is higher than Oncolytics Biotech, Inc.'s net income of -$10.5M. Notably, Organigram Global, Inc.'s price-to-earnings ratio is 15.77x while Oncolytics Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organigram Global, Inc. is 0.92x versus -- for Oncolytics Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OGIOrganigram Global, Inc.0.92x 15.77x $45.6M $14.3M ONCYOncolytics Biotech, Inc.-- -- -- -$10.5M
-
Which has Higher Returns OGI or TLRY?
Tilray Brands, Inc. has a net margin of 31.43% compared to Organigram Global, Inc.'s net margin of -20%. Organigram Global, Inc.'s return on equity of 4.54% beat Tilray Brands, Inc.'s return on equity of -98.18%.
Company Gross Margin Earnings Per Share Invested Capital OGIOrganigram Global, Inc.6.91% $0.10 $275.7M TLRYTilray Brands, Inc.24.43% -$0.41 $1.9B -
What do Analysts Say About OGI or TLRY?
Organigram Global, Inc. has a consensus price target of --, signalling upside risk potential of 137.96%. On the other hand Tilray Brands, Inc. has an analysts' consensus of $11.73 which suggests that it could grow by 59.31%. Given that Organigram Global, Inc. has higher upside potential than Tilray Brands, Inc., analysts believe Organigram Global, Inc. is more attractive than Tilray Brands, Inc..
Company Buy Ratings Hold Ratings Sell Ratings OGIOrganigram Global, Inc.4 0 0 TLRYTilray Brands, Inc.2 7 0 -
Is OGI or TLRY More Risky?
Organigram Global, Inc. has a beta of 1.512, which suggesting that the stock is 51.228% more volatile than S&P 500. In comparison Tilray Brands, Inc. has a beta of 1.955, suggesting its more volatile than the S&P 500 by 95.505%.
-
Which is a Better Dividend Stock OGI or TLRY?
Organigram Global, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tilray Brands, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Organigram Global, Inc. pays -- of its earnings as a dividend. Tilray Brands, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OGI or TLRY?
Organigram Global, Inc. quarterly revenues are $45.6M, which are smaller than Tilray Brands, Inc. quarterly revenues of $217.5M. Organigram Global, Inc.'s net income of $14.3M is higher than Tilray Brands, Inc.'s net income of -$43.5M. Notably, Organigram Global, Inc.'s price-to-earnings ratio is 15.77x while Tilray Brands, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organigram Global, Inc. is 0.92x versus 0.89x for Tilray Brands, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OGIOrganigram Global, Inc.0.92x 15.77x $45.6M $14.3M TLRYTilray Brands, Inc.0.89x -- $217.5M -$43.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
34
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
46
ZD alert for Mar 4
Ziff Davis, Inc. [ZD] is up 3.64% over the past day.
Buy
54
KORU alert for Mar 4
Direxion Daily MSCI South Korea Bull 3X Shares [KORU] is up 5.43% over the past day.
Sell
40
PSIX alert for Mar 4
Power Solutions International, Inc. [PSIX] is down 1.4% over the past day.
